You are here

Articles

Posted on Tuesday, August 2, 2011 - 10:01pm
Dr Andrew Goringe,  Consultant Haematologist in Cardiff  recommends that you 'save the date' for this years annual CML patient/carer day on 12 November 2011 in Cardiff.
Posted on Saturday, June 25, 2011 - 7:47pm
In May, 2011, 30 scientists from 14 countries met at the International Agency for Research on Cancer (IARC) in Lyon, France, to assess the carcinogenicity of radiofrequency electromagnetic fields (RF-EMF).
Posted on Friday, June 24, 2011 - 12:01pm
Bafetinib (formerly known as INNO-406) is an orally bioavailable, rationally designed, dual Bcr-Abl and Lyn-kinase inhibitor. According to a study published in the journal Blood (Dec. 1, 2005), bafetinib is 25 to 55...
Posted on Friday, June 17, 2011 - 10:29am
Simona Soverini1,*, Andreas Hochhaus2, Franck E Nicolini3, Franz Gruber4, Thoralf Lange5, Giuseppe Saglio6, Fabrizio Pane7, Martin C Müller8, Thomas Ernst2, Gianantonio Rosti1, Kimmo Porkka9, Michele Baccarani1,...
Posted on Friday, June 10, 2011 - 12:34pm
Cancer drug protest 2.58PM Thu Jun 9 2011
Posted on Wednesday, May 11, 2011 - 3:23pm
Please lend your support to our urgent appeal that NICE recognise the reality of targeted cancer therapies and personalised medicine by...
Posted on Wednesday, May 11, 2011 - 2:50pm
please use one or more of the template versions to send to your MP You can change the wording depending on how you want to address the issues. The versions are in word format so you should be able to copy and paste...
Posted on Tuesday, May 10, 2011 - 11:48am
Contact your Councillors, MP, MEPs, MSPs, or Northern Ireland, Welsh and London AMs for free
Posted on Tuesday, May 3, 2011 - 3:50pm
Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib...
Posted on Wednesday, April 27, 2011 - 8:11pm
  New Strategies for Chronic Myelogenous Leukemia Despite the major advances in therapy with the successes of imatinib and second-generation tyrosine kinase inhibitors, there is room for improving the management...
Posted on Thursday, April 21, 2011 - 6:15pm
Considerations in the Management of Patients With Philadelphia Chromosome–Positive Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy Hagop Kantarjian and Jorge Cortes MD Anderson Cancer Center,...
Posted on Friday, March 25, 2011 - 4:29pm
  Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
Posted on Friday, March 25, 2011 - 4:24pm
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
Posted on Friday, March 25, 2011 - 4:20pm
Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Passing the Baton Jason Gotlib, MD, MS September 1, 2010